AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01606137
Drug: GW-1000-02
RxNorm normalized name: GW-559090
DrugBank: GW-559090 (DB06508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
Trial: NCT00135070
Drug: Detemir
RxNorm normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02061800
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
Trial: NCT02320318
Drug: Ibodutant 10 mg
RxNorm normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, once daily.
Trial: NCT00528437
Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
Trial: NCT00560183
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)
RxNorm normalized name: Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, four different mg dosage strengths
Trial: NCT02094937
Drug: Fluticasone Furoate/Vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
Trial: NCT02094937
Drug: Fluticasone Furoate 100 mcg
RxNorm normalized name: fluticasone furoate 100 mcg/inh inhalation powder
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
Trial: NCT02094937
Drug: Fluticasone Propionate 250 mcg
RxNorm normalized name: fluticasone propionate 250 MCG/ACTUAT Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
Trial: NCT02094937
Drug: Fluticasone Propionate 100 mcg
RxNorm normalized name: fluticasone propionate 100 MCG/ACTUAT Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
Trial: NCT02094937
Drug: Fluticasone Furoate Placebo
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
Trial: NCT02094937
Drug: Fluticasone Propionate Placebo
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
Trial: NCT01237964
Drug: Xiaflex (FDA approved collagenase)
RxNorm normalized name: Xiaflex
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
Trial: NCT01213550
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04263454
Drug: Endotoxin, Escherichia Coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
Trial: NCT01016561
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04611971
Drug: Benlysta
RxNorm normalized name: Benlysta
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benlysta injection will be administered subcutaneously.
Trial: NCT04611971
Drug: Candin
RxNorm normalized name: Candin
DrugBank: Candida albicans (DB10429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candin will be administered intradermally along with NaCl solution.
Trial: NCT01402583
Drug: PEG IFN/Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PEG IFN/Ribavirin
Trial: NCT04589026
Drug: Cosentyx
RxNorm normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cosentyx injection will be administered subcutaneously.
Trial: NCT04589026
Drug: Candin
RxNorm normalized name: Candin
DrugBank: Candida albicans (DB10429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candin will be administered interadermally along with NaCl solution.
Trial: NCT01789294
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
Trial: NCT04484012
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04471597
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
Trial: NCT01473056
Drug: JTK-853
RxNorm normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, twice a day for 3 days
Trial: NCT00634283
Drug: venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine IR 150mg
Trial: NCT01880099
Drug: Galantamine 8mg
RxNorm normalized name: galantamine 8 MG
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8mg of galantamine compared to placebo
Trial: NCT01880099
Drug: Galantamine 16mg
RxNorm normalized name: galantamine hydrobromide 16 MG
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16mg of galantamine compared to placebo
Trial: NCT03083132
Drug: modafinil 50mg
RxNorm normalized name: ARMODAFINIL 50MG TAB
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 capsule oral daily
Trial: NCT01473056
Drug: Dose 2 JTK-853
RxNorm normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, twice a day for 3 days
Trial: NCT01473056
Drug: Dose 3 JTK-853
RxNorm normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, three times a day for 3 days
Trial: NCT01473056
Drug: Dose 4 JTK-853
RxNorm normalized name: JTK-853
DrugBank: JTK-853 (DB13095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, twice a day for 3 days
Trial: NCT01035320
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
Trial: NCT02061800
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
Trial: NCT02061800
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
Trial: NCT03687021
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Different routes of administration of progesterone; Whether there is endometriosis
Trial: NCT00563303
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 48mL from Day 1 to Day 6
Trial: NCT04425824
Drug: Toripalimab combine with Rituximab
RxNorm normalized name: Toripalimab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).
Trial: NCT04672330
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
Trial: NCT06478355
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
Trial: NCT01092143
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 671800
Trial: NCT01092143
Drug: Fluticasone propionate placebo
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo matching Fluticasone propionate
Trial: NCT01092143
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate
Trial: NCT01092143
Drug: BI 671800 Placebo
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 671800
Trial: NCT02407470
Drug: Rabbit antithymoglobulin (ATG)
RxNorm normalized name: Rabbit ATG
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Trial: NCT03163784
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic pre-treatment
Trial: NCT01226043
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous
Trial: NCT00092690
Drug: Comparator: atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01520454
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV saline at 0.83 mL/kg/hr for six hours
Trial: NCT01520454
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Trial: NCT02185846
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
RxNorm normalized name: dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02185846
Drug: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
RxNorm normalized name: dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01805271
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (5 or 10 mg/day, i.e. 1 or 2 tablets/day)
Trial: NCT02542150
Drug: acetate
RxNorm normalized name: Acetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
Trial: NCT02542150
Drug: alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan.
Trial: NCT01122472
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily for 3 weeks every 4 weeks for 24 months
Trial: NCT02466373
Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clonidine intravenous
Trial: NCT02061800
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
Trial: NCT03813771
Drug: Benepali
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
Trial: NCT03813771
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
Trial: NCT03813771
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
Trial: NCT02993159
Drug: Afimoxifene
RxNorm normalized name: Afimoxifene
DrugBank: Afimoxifene (DB04468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to the breast
Trial: NCT02993159
Drug: Tamoxifen Citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01324063
Drug: amsacrine
RxNorm normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01720212
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01464944
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
Trial: NCT01464944
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
Trial: NCT01324063
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01324063
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03672318
Drug: CAR138 T Cells
RxNorm normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days.
Trial: NCT00650234
Drug: Metformin Hydrochloride ER Tablets 500 mg
RxNorm normalized name: metformin hydrochloride Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg, single dose fasting
Trial: NCT02061800
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
Trial: NCT06135675
Drug: TNP-2092 capsules
RxNorm normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration orally.
Trial: NCT03555890
Drug: Levocetirizine IRT 5 mg
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
Trial: NCT01278160
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
Trial: NCT01278160
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
Trial: NCT04096170
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
Trial: NCT02061800
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
Trial: NCT00077051
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00077051
Drug: cytochlor
RxNorm normalized name: Cytochlor
DrugBank: Cytochlor (DB12383)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00077051
Drug: tetrahydrouridine
RxNorm normalized name: Tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01278160
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
Trial: NCT02378623
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
Trial: NCT01822496
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22.
Trial: NCT01822496
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
Trial: NCT01822496
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)